循環器ジャーナル69巻4号

2021年10月発行

特集 プレシジョン・メディシン時代における腫瘍循環器学の重要性 Ⅰ章　腫瘍循環器学とは

がん治療成績の向上と腫瘍循環器学の重要性

著者： 勝俣範之¹

所属機関： ¹日本医科大学武蔵小杉病院腫瘍内科

ページ範囲：P.530 - P.537

Point
・がん治療関連心血管疾患（CTRCD）の概念を理解する．
・CTRCDを引き起こすがん薬物療法について知っておく．
・心筋障害を起こすがん薬物療法とその対応策を知っておく．

参考文献

1) 国立がん研究センターがん情報センター：がんの統計．2021

2) Shelburne N, Simonds NI, Adhikari B, et al:Changing Hearts and Minds:Improving Outcomes in Cancer Treatment-Related Cardiotoxicity. Curr Oncol Rep 21:9, 2019

3) Guha A, Armanious M, Fradley MG:Update on cardio-oncology:Novel cancer therapeutics and associated cardiotoxicities. Trends Cardiovasc Med 29:29-39, 2019

4) Johnson DB, Balko JM, Compton ML, et al:Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med 375:1749-1755, 2016

5) Cardinale D, Colombo A, Lamantia G, et al:Anthracycline-Induced Cardiomyopathy. Clinical Relevance and Response to Pharmacologic Therapy. J Am Coll Cardiol 55:213-220, 2010

6) Moslehi JJ:Cardiovascular Toxic Effects of Targeted Cancer Therapies. N Engl J Med 375:1457-1467, 2016

7) Yang JC, Sequist LV, Geater SL, et al:Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations:a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol 16:830-838, 2015

8) Cicenas S, Geater SL, Petrov P, et al:Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy（IUNO study）. Lung Cancer 102:30-37, 2016

9) Chan A, Delaloge S, Holmes FA, et al:Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer（ExteNET）:a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 17:367-377, 2016

10) Martin M, Holmes FA, Ejlertsen B, et al:Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer（ExteNET）:5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18:1688-1700, 2017

11) Mok TS, Wu YL, Ahn MJ, et al:Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med 376:629-640, 2017

12) Goss G, Tsai CM, Shepherd FA, et al:Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer（AURA2）:a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 17:1643-1652, 2016

13) Abbas HA, Wierda WG:Acalabrutinib:A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies. Front Oncol 11:668162, 2021

14) Peters S, Camidge DR, Shaw AT, et al:Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med 377:829-838, 2017

15) Cortes JE, Gambacorti-Passerini C, Deininger MW, et al:Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia:Results From the Randomized BFORE Trial. J Clin Oncol 36:231-237, 2018

16) Choueiri TK, Halabi S, Sanford BL, et al:Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk:The alliance A031203 CABOSUN trial. J Clin Oncol 35:591-597, 2017

17) Choueiri TK, Escudier B, Powles T, et al:Cabozantinib versus everolimus in advanced renal cell carcinoma（METEOR）:final results from a randomised, open-label, phase 3 trial. Lancet Oncol 17:917-927, 2016

18) Soria JC, Tan DSW, Chiari R, et al:First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer（ASCEND-4）:a randomised, open-label, phase 3 study. Lancet 389:917-929, 2017

19) Shaw AT, Ou SHI, Bang YJ, et al:Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371:1963-1971, 2014

20) Zwaan CM, Rizzari C, Mechinaud F, et al:Dasatinib in children and adolescents with relapsed or refractory leukemia:results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. J Clin Oncol 31:2460-2468, 2013

21) Miklos D, Cutler CS, Arora M, et al:Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood 130:2243-2250, 2017

22) Motzer RJ, Hutson TE, Glen H, et al:Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma:A randomised, phase 2, open-label, multicentre trial. Lancet Oncol 16:1473-1482, 2015

23) Hochhaus A, Saglio G, Hughes TP, et al:Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase:5-year update of the randomized ENESTnd trial. Leukemia 30:1044-1054, 2016

24) Cortes JE, Kim DW, Pinilla-Ibarz J, et al:A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 369:1783-1796, 2013

25) Grothey A, Van Cutsem E, Sobrero A, et al:Regorafenib monotherapy for previously treated metastatic colorectal cancer（CORRECT）:An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303-312, 2013

26) Ravaud A, Motzer RJ, Pandha HS, et al:Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med 375:2246-2254, 2016

27) Planchard D, Smit EF, Groen HJM, et al:Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer:an open-label, phase 2 trial. Lancet Oncol 18:1307-1316, 2017

28) Mahoney KM, Ackerman A, Cho DC, et al:Vemurafenib-induced cardiac tamponade:A rare but potentially life-threatening complication. J Clin Oncol 31:e364-e366, 2013

29) Stone RM, Mandrekar SJ, Sanford BL, et al:Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 Mutation. N Engl J Med 377:454-464, 2017

30) Robson M, Im SA, Senkus E, et al:Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Eng J Med 377:523-533, 2017

31) Swisher EM, Lin KK, Oza AM, et al:Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma（ARIEL2 Part 1）:an international, multicentre, open-label, phase 2 trial. Lancet Oncol 18:75-87, 2017

32) Mirza MR, Monk BJ, Herrstedt J, et al:Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375:2154-2164, 2016

33) Goetz MP, Toi M, Campone M, et al:MONARCH 3:Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 35:3638-3646, 2017

34) Finn RS, Martin M, Rugo HS, et al:Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375:1925-1936, 2016

35) Sonke GS, Hart LL, Campone M, et al:Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Res Treat 167:659-669, 2018

36) San-Miguel JF, Hungria VTM, Yoon SS, et al:Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone（the PANORAMA 1 trial）:a randomised, placebo-controlled, phase 3 trial. Lancet Haematol 3:e506-e515, 2016

37) Whittaker SJ, Demierre MF, Kim EJ, et al:Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 28:4485-4491, 2010

38) O'Connor OA, Horwitz S, Masszi T, et al:Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma:Results of the pivotal phase Ⅱ BELIEF（CLN-19）study. J Clin Oncol 33:2492-2499, 2015

39) Stein EM, DiNardo CD, Pollyea DA, et al:Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 130:722-731, 2017

40) Dreyling M, Morschhauser F, Bouabdallah K, et al:Phase Ⅱ study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol 28:2169-2178, 2017

41) Bowles EJA, Wellman R, Feigelson HS, et al:Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment:A retrospective cohort study. J Nat Cancer Inst 104:1293-1305, 2012

42) Von Minckwitz G, Procter M, De Azambuja E, et al:Adjuvant pertuzumab and trastuzumab in early her2-positive breast cancer. N Engl J Med 377:122-131, 2017

43) Rittmeyer A, Barlesi F, Waterkamp D, et al:Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer（OAK）:a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255-265, 2017

44) Heery CR, O' Sullivan-Coyne G, Madan RA, et al:Avelumab for metastatic or locally advanced previously treated solid tumours（JAVELIN Solid Tumor）:a phase 1a, multicohort, dose-escalation trial. Lancet Oncol 18:587-598, 2017

45) Powles T, O'Donnell PH, Massard C, et al:Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma:Updated results from a phase 1/2 open-label study. JAMA Oncol 3:e172411, 2017

46) El-Khoueiry AB, Sangro B, Yau T, et al:Nivolumab in patients with advanced hepatocellular carcinoma（CheckMate 040）:an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389:2492-2502, 2017

47) Fuchs CS, Doi T, Jang RWJ, et al:KEYNOTE-059 cohort 1:Efficacy and safety of pembrolizumab（pembro）monotherapy in patients with previously treated advanced gastric cancer. J Clin Oncol 35:4003, 2017

48) Kantarjian H, Stein A, Gökbuget N, et al:Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376:836-847, 2017

49) Prince HM, Kim YH, Horwitz SM, et al:Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma（ALCANZA）:an international, open-label, randomised, phase 3, multicentre trial. Lancet 390:555-566, 2017

50) Marcus R, Davies A, Ando K, et al:Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 377:1331-1344, 2017

51) van Oers MHJ, Kuliczkowski K, Smolej L, et al:Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia（PROLONG）:An open-label, multicentre, randomised phase 3 study. Lancet Oncol 16:1370-1379, 2015

52) Tap WD, Jones RL, Van Tine BA, et al:Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma:an open-label phase 1b and randomised phase 2 trial. Lancet 388:488-497, 2016

53) Neelapu SS, Locke FL, Bartlett NL, et al:Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma. N Engl J Med 377:2531-2544, 2017

54) Holstein SA, Jung SH, Richardson PG, et al:Updated analysis of CALGB（Alliance）100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma:a randomised, double-blind, phase 3 trial. Lancet Haematol 4:e431-e442, 2017

55) Miguel JS, Weisel K, Moreau P, et al:Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma（MM-003）:a randomised, open-label, phase 3 trial. Lancet Oncol 14:1055-1066, 2013

56) Siegel D, Martin T, Nooka A, et al:Integrated safety profile of single-agent carfilzomib:Experience from 526 patients enrolled in 4 phase Ⅱ clinical studies. Haematologica 98:1753-1761, 2013

57) Fizazi K, Tran N, Fein L, et al:Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377:352-360, 2017

58) Stilgenbauer S, Eichhorst B, Schetelig J, et al:Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion:a multicentre, open-label, phase 2 study. Lancet Oncol 17:768-778, 2016

59) Yao JC, Fazio N, Singh S, et al:Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract（RADIANT-4）:A randomised, placebo-controlled, phase 3 study. Lancet 387:968-977, 2016

60) Kenigsberg B, Wellstein A, Barac A:Left Ventricular Dysfunction in Cancer Treatment:Is it Relevant? JACC Heart Fail 6:87-95, 2018

61) Armenian SH, Lacchetti C, Barac A, et al:Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers:American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 35:893-911, 2017